Holland Protonen Therapie Centrum
- Address
- lock Available on a paid plan
Neoplasms and Digestive System Diseases
At Holland Protonen Therapie Centrum in Delft, the clinical research focus includes oesophageal cancer and oesophagogastric junction cancer, with a strong emphasis on treatment strategies for HER2 positive esophageal adenocarcinoma. The trials are designed to assess whether new combinations of therapy can improve survival and strengthen disease control for patients with these challenging cancers.
- Evaluating the benefit of adding targeted treatment to standard care for resectable HER2 positive esophageal adenocarcinoma
- Studying outcomes in oesophageal cancer and oesophagogastric junction cancer through more intensive treatment approaches
- Focusing on better survival results and longer-lasting control of digestive system tumors
This research combines therapeutic techniques and equipment with oncology care, reflecting a broader effort to improve how treatment is delivered and how effectively it works for people with upper gastrointestinal cancers.
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The site is also involved in research on treatment optimization, where clinical trials examine how to improve the effectiveness of current cancer therapy rather than simply introducing new drugs. This includes studying whether more comprehensive treatment plans can lead to better long-term outcomes for patients with locally advanced disease.
- Assessing progression-free survival after total neoadjuvant treatment for node-positive oesophageal adenocarcinoma
- Comparing treatment strategies to determine which approach offers stronger disease control in oesophagogastric junction cancer
- Supporting research into more precise and effective care for patients treated at the Holland Protonen Therapie Centrum
Overall, the trials at this center are centered on improving diagnostics, refining therapeutics, and advancing care for cancers of the esophagus and nearby digestive tract.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Amsterdam UMC Stichting1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Holland Protonen Therapie Centrum
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Total Neoadjuvant Therapy with Folinic Acid, Fluorouracil, and Docetaxel in Lymph Node-Positive Oesophagogastric Junction Adenocarcinoma | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Phase II | Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 1 | Unknown | 2025-09-12 | 2025-09-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.